Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by CRISPR Therapeutics
CTX112 (zugocabtagene geleucel) is an allogeneic CAR T-cell therapy made from human T lymphocytes engineered to express a chimeric antigen receptor specific for CD19 and gene-edited with CRISPR-Cas9 to remove endogenous TCR, TGFbRII and Regnase-1. It recognizes CD19-expressing tumor cells and kills them through cytotoxic T-lymphocyte activity. It is studied in B-cell lymphomas and chronic lymphocytic leukemia/small lymphocytic lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05643742 | Phase 1/2 | B-cell Lymphoma | Recruiting | CRSP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B-cell LymphomaB-cell MalignancyFollicular LymphomaLarge B-cell LymphomaMantle Cell LymphomaMarginal Zone LymphomaNon-Hodgkin Lymphoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.
See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRSP catalysts and pipeline →